Log in

NASDAQ:ADMSAdamas Pharmaceuticals Stock Price, Forecast & News

$2.61
-0.03 (-1.14 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.57
Now: $2.61
$2.67
50-Day Range
$2.48
MA: $2.63
$2.93
52-Week Range
$1.90
Now: $2.61
$7.78
Volume465,475 shs
Average Volume214,188 shs
Market Capitalization$73.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
Read More
Adamas Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.51 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADMS
CUSIPN/A
Phone510-450-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.64 million
Book Value($0.03) per share

Profitability

Net Income$-105,190,000.00
Net Margins-160.44%

Miscellaneous

Employees159
Market Cap$73.50 million
Next Earnings DateN/A
OptionableOptionable
$2.61
-0.03 (-1.14 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADMS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADMS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Adamas Pharmaceuticals (NASDAQ:ADMS) Frequently Asked Questions

How has Adamas Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adamas Pharmaceuticals' stock was trading at $3.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADMS stock has decreased by 14.4% and is now trading at $2.61.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Adamas Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Adamas Pharmaceuticals
.

How were Adamas Pharmaceuticals' earnings last quarter?

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) released its quarterly earnings data on Thursday, August, 6th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.24. Adamas Pharmaceuticals had a negative net margin of 160.44% and a negative return on equity of 806.54%.
View Adamas Pharmaceuticals' earnings history
.

What price target have analysts set for ADMS?

9 analysts have issued twelve-month price objectives for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they anticipate Adamas Pharmaceuticals' share price to reach $16.14 in the next year. This suggests a possible upside of 518.5% from the stock's current price.
View analysts' price targets for Adamas Pharmaceuticals
.

Has Adamas Pharmaceuticals been receiving favorable news coverage?

Media stories about ADMS stock have trended positive this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 2.1 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Adamas Pharmaceuticals
.

Are investors shorting Adamas Pharmaceuticals?

Adamas Pharmaceuticals saw a decrease in short interest during the month of July. As of July 31st, there was short interest totaling 715,600 shares, a decrease of 23.2% from the July 15th total of 931,400 shares. Based on an average daily trading volume, of 431,400 shares, the days-to-cover ratio is currently 1.7 days. Currently, 3.2% of the company's shares are short sold.
View Adamas Pharmaceuticals' Current Options Chain
.

Who are some of Adamas Pharmaceuticals' key competitors?

What other stocks do shareholders of Adamas Pharmaceuticals own?

Who are Adamas Pharmaceuticals' key executives?

Adamas Pharmaceuticals' management team includes the following people:
  • Dr. Gregory T. Went, Co-Founder, Chairman & CEO (Age 55)
  • Mr. Alfred G. Merriweather, Chief Financial Officer (Age 65)
  • Mr. Christopher B. Prentiss, Chief Accounting Officer (Age 44)
  • Ashleigh Barreto, Director of Corp. Communications & Investor Relations
  • Ms. Jennifer J. Rhodes, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 49)

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Who are Adamas Pharmaceuticals' major shareholders?

Adamas Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (2.67%), Emerald Advisers LLC (2.38%), Emerald Mutual Fund Advisers Trust (2.21%), Deltec Asset Management LLC (1.26%) and SG Americas Securities LLC (0.13%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes.
View institutional ownership trends for Adamas Pharmaceuticals
.

Which major investors are selling Adamas Pharmaceuticals stock?

ADMS stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, and SG Americas Securities LLC. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, and Christopher B Prentiss.
View insider buying and selling activity for Adamas Pharmaceuticals
.

Which major investors are buying Adamas Pharmaceuticals stock?

ADMS stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust.
View insider buying and selling activity for Adamas Pharmaceuticals
.

How do I buy shares of Adamas Pharmaceuticals?

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Adamas Pharmaceuticals' stock price today?

One share of ADMS stock can currently be purchased for approximately $2.61.

How big of a company is Adamas Pharmaceuticals?

Adamas Pharmaceuticals has a market capitalization of $73.50 million and generates $54.64 million in revenue each year. The specialty pharmaceutical company earns $-105,190,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.

What is Adamas Pharmaceuticals' official website?

The official website for Adamas Pharmaceuticals is www.adamaspharma.com.

How can I contact Adamas Pharmaceuticals?

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.